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Summary: We developed a luminescence immunoassay (LIA) for follitropin, based on the synthesis of a
follitropin-N-(4-aminobutyl)-N-ethylisoluminol conjugate. The luminescence tracer was purified by gel chro-
matography. Antibody-bound and non-bound tracer fractions were separated by using a second antibody
reagent bound to magnetic particles. The assay can be performed within 24 hours and is sufficiently sensitive
for the measurement of all clinically relevant follitropin concentrations including the subnormal r nge.
Introduction
In view of the well-known disadvantages of radioac-
tive labels, non-isotopic immunoassays have been
widely investigated in recent years (2 — 6). This paper
describes the development and validation of a lumi-
nescence immunoassay (LIA) for human follitropin
(follicle stimulating hormone, FSH), based on the
synthesis pf an FSH-N-(4-aminobutyl)-N-ethylisolu-
minol conjugate and a solid phase (magnetic particle)
double antibody Separation technique.
Materials
Ν,Ν-Dimethylformamide water-free 99 + % (H?O < 0.005%),
Aldrich Steinheim 22-705-6.
NjN'-Dicyclohexyl-carbodiiinide, Sigma, M nchen, D 3128.
N-Hydroxysuccinimide Sigin , M nchen^ H 7377.
N-(4-An nobutyl)-N-ethylisoluminol (ABEI), 97% pure,
Sigma, M nchen, A 0156.
Succinic anhydride, Sigma, M nchen, S 7626.
Catalase from bovine liver, Sigma, M nchen, C 3155.
Urea hydrogen peroxide (H2O2 content approx. 35%), Sigma,
M nchen, U 1753.
Sephadex G-50 fme, Pharmacia, Uppsala, particle size
20-80μπι.
Part of Ph. D. thesis of A. Samira.
FSH-human-pituitary Research Standard A, 4IU/Ampoule
(MRC London).
Follitropin highly purified batch CPD 313 (3500 lU/mg) (gen-
erous gift of Prof. W. R. Butt, Dept. of Clin. Endocrinology,
Birmingham, Midland Hospital for Women, England).
Rabbit-anti-FSH-antibody Hoe-RCL-2665, Hoechst AG,
Frankfurt/Main.
FSH-IRMA kit Nichols Institute, San Juan Capistrano, Calif.,
USA.
ΜΑΙΑ Reagent (Anti-rabbit IgG covalently bound to para-
magnetic particles), Serono, Freiburg.
Berthold luminometer (CliniLumat LB 9502).
Methods
Tracer was prepared by a modiflcation of the method of Barnard
et al. (2, 3).
The reactions were carried out s follows:
Reaction a: 10 μτηοΐ N-(4-aminobutyl)-N-ethylisoluminol
(ABEI; 2.76 mg) were dissolved in 160 μg dry dimethylform-
amide in a water bath at 40 — 50 °C for a few minutes, and 10
μιηοΐ (l mg) succinic anhydride were dissolved in 2 ml dry
pyridine. Both Solutions were gassed with dry nitrogen and
mixed. The reaction tube was firmly plugged and left in the
dark at room temperature for 24—72 nours.
Reaction b: Freshly prepared ABEI-hemisuccinamide (ABEI-
H) was flrst made free of pyridine and dimethylformamide by
distillation under low pressure in a vacuum distillation appa-
ratus in the dark. The residue was dissolved in 25 μΐ dry di-
methylformamide and incubated with 10 μηιοί (11.5 mg) N-
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hydroxysiiccinimidc and 30 μηιοί Ν,Ν'-dicyclohexylcarbodi-
imidc (6.18 mg) in 40 μΐ ciry dimcthylformamide (total incu-
balion volume approximalcly 65 μΐ) for 24 hours in thc dark.
Reaction c: 100 μg highly purificd follitropin was dissolved in
1000 μΐ phosphatc buffer (Na2HPO4 0.05 mol/1, pH 8.0), and
200 μΐ of this solution vvere incubated vvith 10 μΐ of the reaction
product *%b" (ABEl-hemisuccinamide active ester) at 4 °C for
24 hours in the dark.
The follitropin isoluminol conjugate was separated from the
resulting mixture of reaction uc" by filtration on a column of
Sephadex G-50 fine (length 25 cm, diameter l cm) using for
elution 0.05 mol/1 Tris-HCl buffer (pH 7.5) containing 0.02
mol/1 sodium azide. The eluate was collected in thirty l ml
fractions. Luminescence reactivity was measured in each frac-
tion after dilution vvith Soerenserfs phosphate buffer containing
l0 g/l bovine serum albumin using a Berthold luminometer.
The luminescence immunoassay was performed according to
the scheine in table l. For use in the assay, the ΜΑΙΑ reagent
was washed once in assay buffer, decanted and resuspended in
the twofold buffer volume. After the second incubation, the
tubes were decanted using a magnetic rack, washed three times
with Soerensen's phosphate buffer (10 g/l bovine serum albu-
niin) and catalase solution was added. Thereafter luminescence
was measured in a Berthold luminometer, which automatically
started the luminescence reaction by injecting urea hydrogen
peroxide solution in the dark.
Tab. 1. Assay protocol for follitropin-LIA.
NSB: Non-specific tracer binding;
B0: Tracer binding in absence of unlabelled follitropin.
ΜΑΙΑ: Anti-rabbit IgG covalently bound to suitable
paramagnetic particles (Suspension in assay buffer)
Assay protocol
Reagents NSB Standards
(samples)
ABEI-H-folIitropin
Assay buffer
Standards (samples)
Follitropin antibody
ΜΑΙΑ Suspension
100 μΐ 100 μΐ 100 μΐ
200 μΐ 100 μΐ
100 μΐ
100 μΐ 100 μΐ
incubation for 20 hours at room
temperature
25 μΐ 25 μΐ 25 μΐ
incubation for 10 minutes at
room temperature
decant in magnetic rack and wash
3 times in Soerensen's phosphate
buffer (l ml) containing 10 g/l bo-
vine serum albumin
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Fig. 1. Gel Chromatographie pattern of the follitropin-ABEI-
H-conjugate. The bulk of follitropin immunoreactivity
is found in the first peak of luminescence.
RLU = Relative light units.
IU/1. For use in the assay the mixture was dil ted 75-
fold in assay buffer (Soerensetfs phosphate buffer
containing 30 g/l bovine serum albumin) to yield a
follitropin concentration of about 20 IU/1.
Figure 2 shows a typical Standard curve. The detection
limit, defined s the follitropin concentration corre^
sponding to the riiean value of relative light units
(RLU) minus two Standard deviations of a twentyfold
determination of the zero Standard, was 0.59 IU/1/
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Fig. 2. Typical Standard curve of follitropin-LlA. Detection
limit 0.59 mIU/1.
Results
Figure l shows that two peaks of luminescence were
found in the eluates of the Sephadex G 50 fine col-
umn. When follitropin was measured in each eluate
fraction by an immunoradiometric assay (Nichols In-
stitute), peak 2 was found to be devoid of follitropin
reactivity. The highest follitropin immunoreactivity
was found in tubes 7—9 which were mixed for use s
the luminescence tracer. The follitropin concentration
of the combined fraction was approximately 1500
Precision profile
Intraassay coefficients of Variation were 4.8%, 3.1%
and 6.7% in the ranges of 10, 30 and 90 IU/1 (n = 20)
respectively. Interassay coefficients of Variation were
found to be 5.9%, 5.8% and 9.4% in the same ranges
(n = 20).
The specificity of the antiserum used is demonstrated
by the cross reactions at 50% inhibition (1): follitropin
100%, thyrotropin 1.9%, lutropin 0.2%, human cho*·
rionic gonadotropin: unmeasunibly low.
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Accuracy
Increasing amounts of Standard were added to the
same serum sample and aliquots were assayed (recov-
ery test). Figure 3 demonstrates the straight regression
line obtained for the added amount versus measured
amount, demonstrating the equivalence of follitropin
in Standard and serum and the absence of matrix
influences (see also tab. 2). Figure 4 shows the results
of the parallelism test. Increasing dilutions of a serum
sample with high follitropin concentration (menopau-
sal serum) were assayed. The straight linear regression
for the dilution factor versus the measured amounts
of follitropin proved that the assay is independent of
concentrations and interferences which may be pres-
ent in the sample (see also tab. 3).
Figure 5 demonstrates the excellent correlation of LIA
results with IRMA values in 20 samples including 6
sera of menopausal patients, of one patient with pri-
mary hypogonadism, of 10 normal persons and of 3
patients with hypogonadotropic hypogonadism.
60Ί
Tab. 2. Recovery test.
20 40
Follitropin (added) [IU/1]
Fig. 3- Recovery test (see text)
y = 1.0504x + 4.95; r = 0.9999; n = 4.
60
Endogenous
follitropin
IU/1
4.8
4.8
4.8
4.8
4.8
Added
follitropin
IU/1
0.0
2.0
5.0
20.0
50.0
Expected
follitropin
IU/1
4.8
6.8
9.8
24.8
54.8
Recovered
follitropin
IU/1
4.8
7.1
10.0
26.2
57.4
Tab. 3. Parallelism test.
Dilution Measured
follitropin
(IU/1)
Result corrected
with dilution factor
None
1: 2
1: 4
1: 8
1:16
1:32
86.6
42.5
19.8
11.2
5.4
2.4
85.0
79.2
89.6
86.4
79.2
801
70
^ 60
50
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Fig. 4. Parallelism test (see text)
y = IjOlx + 1.9365; r = 0.9991; n = 6.
Fig. 5. Correlation of follitropin-LIA results with a reference
follitropin-IRMA (Nichols Institute),
y = 0,9907x ^ 0.1893; r = 0.9987; n = 20.
Discussion
The use of radioactive tracers in immunoassays has
certain drawbacks such s human contact with radio-
active material and the short shelf life of the labelled
antigens. The luminescence immunoassay (LIA) has
solved these probleras (4).
Follitropin determinations are being increasingly re-
quested for the evaluation of patients with delayed
puberty, amenorrhoea, pituitary tumours and infer-
tility. We therefore developed — to the best of our
knowledge for the first time — a follitropin LIA for
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 29,1991 / No. 3
192 Biro et al.: Luminescence immunoassay for foJlitropin
clinical use. Labelling of highly purified follitropin
with ABEI was performed in 3 subsequent Steps in a
modification of the method of Barnard et al. (2, 3).
No attempt was made to purify the intermediate re-
action products, because of the imstable ilature of
ABEI-hemisuccinamide active ester (7), and because
final tracer purification was necessary anyway. The
resulting stable follitropin-ABEI-hemisuccinamide
conjugate was easily purified by gel chromatography.
Many experiments were performed to find the optimal
ratios for the final reaction of ABEI-hemisuccinamide
active ester with follitropin. Although the concentra-
tions indicated above may not be optimal, they led
to the highest quantity of the final reaction product.
The conjugate has an excellent yield of luminescence
impulses, very little non-specific binding and is stable
for at least 9 months.
Separation of antibody-bound and non-bound tracer
fractions was readily performed with a commercially
available paramagnetic particle "second antibody"
reagent. It proved to be essential to dilute this reagent
in buffer cpntaining only 10 g/l;Albumin, äs higher
concentrations of albumin led to a quenching of lu-
minescence activity. The assay can be performed at
room temperature within 24 hours. It is well repro-
ducible, has a sensitivity which allows the measure-
ment of all clinically relevant values including sub-
normal ones, shows good correlation with a widely
used commercial IRMA from a reference laboratory,
and may therefore be recommended for clinical use.
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